|Bid||32.51 x 1600|
|Ask||32.83 x 100|
|Day's Range||32.65 - 32.97|
|52 Week Range||29.83 - 35.38|
|PE Ratio (TTM)||27.50|
|Dividend & Yield||1.28 (3.92%)|
|1y Target Est||N/A|
AbbVie and Pfizer both have great dividends and successful track records over the long run. But which is the better pick now?
Besponsa's FDA approval for use in some leukemia patients continues to position the company as a leading player in cancer treatment.
Pfizer's last 40 years show what it takes to become a millionaire: Buy, hold, and reinvest.